$40.42
+0.02
(+0.05%)▲
Live
Insights on Quidelortho Corp
Revenue is down for the last 2 quarters, 744.0M → 742.6M (in $), with an average decrease of 0.2% per quarter
Netprofit is up for the last 3 quarters, -53.2M → 7.0M (in $), with an average increase of 300.2% per quarter
In the last 1 year, Boston Scientific Corp. has given 34.4% return, outperforming this stock by 90.8%
In the last 3 years, Boston Scientific Corp. has given 61.5% return, outperforming this stock by 126.7%
2.97%
Downside
Day's Volatility :2.97%
Upside
0.0%
6.53%
Downside
52 Weeks Volatility :60.24%
Upside
57.46%
Period | Quidelortho Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -42.28% | 1.9% | 0.0% |
6 Months | -39.01% | 10.7% | 0.0% |
1 Year | -56.37% | 4.6% | -1.1% |
3 Years | -66.43% | 14.2% | -22.1% |
Market Capitalization | 2.6B |
Book Value | $75.05 |
Earnings Per Share (EPS) | -0.15 |
PEG Ratio | 7.19 |
Wall Street Target Price | 82.6 |
Profit Margin | -0.34% |
Operating Margin TTM | 13.49% |
Return On Assets TTM | 2.01% |
Return On Equity TTM | -0.2% |
Revenue TTM | 3.0B |
Revenue Per Share TTM | 44.88 |
Quarterly Revenue Growth YOY | -14.299999999999999% |
Gross Profit TTM | 1.9B |
EBITDA | 736.2M |
Diluted Eps TTM | -0.15 |
Quarterly Earnings Growth YOY | -0.77 |
EPS Estimate Current Year | 2.42 |
EPS Estimate Next Year | 3.86 |
EPS Estimate Current Quarter | 2.05 |
EPS Estimate Next Quarter | 1.49 |
What analysts predicted
Upside of 104.35%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 522.3M | ↑ 88.05% |
Net Income | 74.2M | ↓ 1008.55% |
Net Profit Margin | 14.2% | ↑ 17.14% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 534.9M | ↑ 2.41% |
Net Income | 72.9M | ↓ 1.7% |
Net Profit Margin | 13.63% | ↓ 0.57% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.7B | ↑ 210.66% |
Net Income | 810.3M | ↑ 1011.18% |
Net Profit Margin | 48.76% | ↑ 35.13% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.7B | ↑ 2.22% |
Net Income | 704.2M | ↓ 13.09% |
Net Profit Margin | 41.46% | ↓ 7.3% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.3B | ↑ 92.28% |
Net Income | 548.7M | ↓ 22.08% |
Net Profit Margin | 16.8% | ↓ 24.66% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 3.0B | ↓ 8.34% |
Net Income | -10.1M | ↓ 101.84% |
Net Profit Margin | -0.34% | ↓ 17.14% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 783.8M | ↑ 27.78% |
Net Income | 19.2M | ↓ 0.52% |
Net Profit Margin | 2.45% | ↓ 0.7% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 866.5M | ↑ 10.55% |
Net Income | 30.3M | ↑ 57.81% |
Net Profit Margin | 3.5% | ↑ 1.05% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 846.1M | ↓ 2.35% |
Net Income | 48.8M | ↑ 61.06% |
Net Profit Margin | 5.77% | ↑ 2.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 665.1M | ↓ 21.39% |
Net Income | -53.2M | ↓ 209.02% |
Net Profit Margin | -8.0% | ↓ 13.77% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 744.0M | ↑ 11.86% |
Net Income | -12.7M | ↓ 76.13% |
Net Profit Margin | -1.71% | ↑ 6.29% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 742.6M | ↓ 0.19% |
Net Income | 7.0M | ↓ 155.12% |
Net Profit Margin | 0.94% | ↑ 2.65% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 806.4M | ↓ 13.78% |
Total Liabilities | 380.8M | ↓ 46.23% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 910.9M | ↑ 12.96% |
Total Liabilities | 351.0M | ↓ 7.81% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 105.43% |
Total Liabilities | 538.5M | ↑ 53.39% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↑ 29.89% |
Total Liabilities | 501.0M | ↓ 6.95% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 8.9B | ↑ 264.38% |
Total Liabilities | 3.9B | ↑ 682.66% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 8.6B | ↓ 3.31% |
Total Liabilities | 3.6B | ↓ 9.28% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 8.7B | ↓ 1.89% |
Total Liabilities | 3.9B | ↓ 1.09% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 8.9B | ↑ 2.31% |
Total Liabilities | 3.9B | ↑ 1.58% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.8B | ↓ 0.78% |
Total Liabilities | 3.8B | ↓ 3.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.6B | ↓ 2.69% |
Total Liabilities | 3.5B | ↓ 6.41% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.5B | ↓ 0.13% |
Total Liabilities | 3.6B | ↑ 0.69% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.6B | ↑ 0.28% |
Total Liabilities | 3.6B | ↓ 0.43% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 136.3M | ↑ 392.06% |
Investing Cash Flow | 115.0M | ↓ 126.62% |
Financing Cash Flow | -244.1M | ↓ 190.19% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 134.5M | ↓ 1.36% |
Investing Cash Flow | -27.2M | ↓ 123.69% |
Financing Cash Flow | -98.3M | ↓ 59.73% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 629.8M | ↑ 368.28% |
Investing Cash Flow | -63.3M | ↑ 132.55% |
Financing Cash Flow | -130.3M | ↑ 32.55% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 805.9M | ↑ 27.96% |
Investing Cash Flow | -319.5M | ↑ 404.61% |
Financing Cash Flow | -173.2M | ↑ 32.93% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 885.3M | ↑ 9.86% |
Investing Cash Flow | -1.6B | ↑ 414.57% |
Financing Cash Flow | 252.0M | ↓ 245.52% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.7M | ↓ 104.32% |
Investing Cash Flow | -29.8M | ↓ 98.05% |
Financing Cash Flow | -126.0M | ↓ 130.5% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 169.4M | ↓ 1846.39% |
Investing Cash Flow | -59.3M | ↑ 98.99% |
Financing Cash Flow | -31.7M | ↓ 74.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 188.9M | ↑ 11.51% |
Investing Cash Flow | -68.9M | ↑ 16.19% |
Financing Cash Flow | -59.6M | ↑ 88.01% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.6M | ↓ 116.2% |
Investing Cash Flow | -42.3M | ↓ 38.61% |
Financing Cash Flow | -99.7M | ↑ 67.28% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 41.5M | ↓ 235.62% |
Investing Cash Flow | -21.3M | ↓ 49.65% |
Financing Cash Flow | -48.7M | ↓ 51.15% |
Sell
Neutral
Buy
Quidelortho Corp is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Quidelortho Corp | -14.89% | -39.01% | -56.37% | -66.43% | -35.13% |
Stryker Corporation | -4.59% | 26.35% | 10.88% | 26.25% | 80.99% |
Boston Scientific Corp. | 2.53% | 35.38% | 34.38% | 63.21% | 94.67% |
Edwards Lifesciences Corp. | -5.81% | 24.49% | -1.17% | -8.62% | 48.12% |
Abbott Laboratories | -2.2% | 13.48% | -2.55% | -12.23% | 40.18% |
Medtronic Plc | -2.34% | 12.97% | -9.37% | -37.53% | -5.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Quidelortho Corp | 9.72 | NA | 7.19 | 2.42 | 0.0 | 0.02 | NA | 75.05 |
Stryker Corporation | 39.67 | 39.67 | 2.92 | 11.85 | 0.18 | 0.07 | 0.01 | 48.92 |
Boston Scientific Corp. | 63.57 | 63.57 | 1.8 | 2.25 | 0.09 | 0.04 | NA | 13.16 |
Edwards Lifesciences Corp. | 38.15 | 38.15 | 5.19 | 2.75 | 0.22 | 0.12 | NA | 11.06 |
Abbott Laboratories | 33.36 | 33.36 | 5.99 | 4.61 | 0.15 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 25.58 | 25.58 | 1.52 | 5.2 | 0.08 | 0.04 | 0.03 | 38.95 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Quidelortho Corp | Buy | $2.6B | -35.13% | 9.72 | -0.34% |
Stryker Corporation | Buy | $124.7B | 80.99% | 39.67 | 15.44% |
Boston Scientific Corp. | Buy | $100.0B | 94.67% | 63.57 | 11.18% |
Edwards Lifesciences Corp. | Buy | $52.8B | 48.12% | 38.15 | 23.36% |
Abbott Laboratories | Buy | $185.8B | 40.18% | 33.36 | 13.96% |
Medtronic Plc | Buy | $107.0B | -5.08% | 25.58 | 13.0% |
The Carlyle Group Inc
T. Rowe Price Investment Management,Inc.
Vanguard Group Inc
BlackRock Inc
RIMA MANAGEMENT, LLC
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)
QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.
Organization | Quidelortho Corp |
Employees | 7100 |
CEO | Mr. Michael S. Iskra |
Industry | Health Technology |
Dnp Select Income Closed Fund
$40.42
+0.05%
Masonite International Corp
$40.42
+0.05%
Zillow Group, Inc. - Class C Shares
$40.42
+0.05%
Edgio Inc.
$40.42
+0.05%
Papa John's International Inc.
$40.42
+0.05%
Jpmorgan Betabuilders Europe Etf
$40.42
+0.05%
Marqeta, Inc.
$40.42
+0.05%
Endeavor Group Holdings, Inc.
$40.42
+0.05%
Global X Nasdaq 100 Covered Call Etf
$40.42
+0.05%